Our highly differentiated antimicrobial product pipeline utilizes our patented bisphosphocin™ class to target four high-need indications. Three of these indications are expected to complete Phase 2 clinical trials with adaptive arms providing robust clinical data by 2020.
Bisphosphocins are novel small protonated nucleotide derivative molecules that exert their antibacterial activity by depolarization and rupture of the bacterial cell membranes, causing rapid bacterial cell death. Preclinical studies have demonstrated efficacy against more than 70 bacterial strains, including all the ESKAPE pathogens and clinically isolated bacterial strains such as Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Our bisphosphocin technology currently has 38 patents issued, with coverage extending to 2038.